Dry extracts from Ginkgo biloba and Hypericum perforatum
Helps your healthy organism to maintain good memory and concentration.*
Promotes serenity and restful sleep.*
How and Why It Works?
The hypericin in Hypericum perforatum is a derivative of anthraquinone, which is believed to support the inhibition of monoamine oxidases, takes part in the metabolic processes in the brain and helps the transmission of nerve impulses.*  This helps in maintaining a positive serotonin balance in the central nervous system and the healthy mental functions in long term.*  The hypericin itself in combination with the other phytochemicals – flavonoids, xanthones and tannic compounds influence positively the mood.* [1-4] The content of flavonoids in the dietary supplement VemoHerb® Ginkgo Hypericum is further increased by the addition of the ginkgo flavonoids quercetin, kaempferol and isorhamnetin from the Ginkgo biloba extract.*
The ginkgo flavone glycosides support the blood vessels of the heart and the brain in healthy individuals.* [5-7] These biologically active substances also support the organism in maintaining the nerve cells integrity.* [8, 9] They are believed to help maintaining the normal hormonal balance and the healthy levels of serotonin in the blood, thus supporting nervous relaxation.* As a result, the supplement supports a normal healthy attitude and mood when experiencing occasional simple nervous tension.* VemoHerb® Ginkgo Hypericum is a very suitable supplement in supporting your everyday office activities, helping to keep your mental alertness and wakefulness.* [10 – 12] VemoHerb® Ginkgo Hypericum supports your memory and the ability to concentrate by increasing dopamine concentration in the organism.* [12, 13] It helps maintain your quick reactions for longer periods of time and helps reduce the impact of tiredness.* [12-14]
VemoHerb® Ginkgo Hypericum:
Supports your good mood and memory * [12, 13, 15, 16]
Gently sooths away the tension * [13, 15 – 17]
For relief of occasional sleeplessness * 
Helps to keep your mental alertness and wakefulness when tired from overwork * [11, 14 – 16]
The pack contains
Active substances in one capsule
120 mg dry extract from the leaves of Ginkgo biloba, standardised at 24% ginkgo flavone glycosides; 130 mg dry extract from the aerial part of Hypericum perforatum, standardized at 0.3% hypericin
Recommended daily dose
1 – 3 capsules a day
Directions for use
Take between the meals or as directed on the label.
The product is a food supplement not a medical drug. The product is not a substitute for a varied diet. Do not exceed the recommended daily dose. It is not recommended for pregnant, nursing women and children!
Ginkgo biloba is currently the most thoroughly studied standardized herbal extract in terms of its benefits for the nervous system in supporting the cognitive function.* [5 – 8, 10, 11, 14, 15]
1. Butterweck, Böckers, Korte, Wittkowski, Winterhoff – Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus.
3. Ronald Brenner,Subramoniam Madhusoodanan,Monika Pawlowska,et alPal Czobor – St John's Wort and Major Depression
4. Gaster , Holroyd J. – St John's wort for depression: a systematic review.
5. Christian Ude, Mario Wurglics – Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients
(PDF) Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients.
6. Zhang SJ1, Xue ZY. – Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia.
To discuss the clinical effects of Western medicine therapy assisted by Ginkgo biloba tablet (GBT) on patients with vascular cognitive impairment of none dementia (VCIND).
A total of 80 patients with VCIND were divided into two groups randomly: Conventional treatment group (control group) and combined treatment group. Conventional treatment group was given conventional treatment with anti-platelet aggregation. In this group, 75 mg aspirin was given three times a day for 3 months. While in combined treatment group, 19.2 mg GBT was given three times a day for 3 months together with conventional treatment (anti-platelet aggregation drugs). Montreal cognitive assessment (MoCA) and transcranial Doppler (TCD) were used to observe changes of cognitive ability and cerebral blood flow in VCIND patients before and after treatment in both groups. Then the clinical data were analyzed so as to compare the efficacy in two groups.
After 3 month-treatment in combined treatment group, the scores of executive ability, attention, abstract, delayed memory, orientation in the MoCA were significantly increased compared with those before treatment and those in control group after treatment. Besides, blood flow velocity of anterior cerebral artery increased significantly than that before treatment and that in control group after treatment.
GBT tablet can improve the therapeutic efficacy as well improve cognitive ability and cerebral blood flow supply of patients with VCIND.
7. Santos, Galduróz, Barbieri, Castiglioni, Ytaya, Bueno – Cognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo biloba.
8. Jose Miguel Rubio-Perez and Juana Maria Morillas-Ruiz – A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Alzheimer’s disease (AD) is the most common neurodegenerative disorder to date. Neuropathological hallmarks are β-amyloid (Aβ) plaques and neurofibrillary tangles, but the inflammatory process has a fundamental role in the pathogenesis of AD. Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the complement system, as well as cytokines and chemokines. Cytokines play a key role in inflammatory and anti-inflammatory processes in AD. An important factor in the onset of inflammatory process is the overexpression of interleukin (IL)-1, which produces many reactions in a vicious circle that cause dysfunction and neuronal death. Other important cytokines in neuroinflammation are IL-6 and tumor necrosis factor (TNF)-α. By contrast, other cytokines such as IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, and transforming growth factor (TGF)-β can suppress both proinflammatory cytokine production and their action, subsequently protecting the brain. It has been observed in epidemiological studies that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the risk for developing AD. Unfortunately, clinical trials of NSAIDs in AD patients have not been very fruitful. Proinflammatory responses may be countered through polyphenols. Supplementation of these natural compounds may provide a new therapeutic line of approach to this brain disorder.
9. J. Klein, O. Weichel, M. Hilgert, J. Rupp, S. S. Chatterjee, H. Nawrath – Excitotoxic Hippocampal Membrane Breakdown and its Inhibition by Bilobalide: Role of Chloride Fluxes
10. Yoshitake, Yoshitake, Kehr – The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex.
Experimental and clinical data suggest that extracts of Ginkgo biloba improve cognitive function. However, the neurochemical correlates of these effects are not yet fully clarified. The purpose of this study was to examine the effects of acute and repeated oral administration of the standardized extract EGb 761((R)) on extracellular levels of dopamine, noradrenaline and serotonin (5-HT), and the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the prefrontal cortex (PFC) and striatum of conscious rats.
Monoamines and their metabolites were monitored by the use of microdialysis sampling and HPLC with electrochemical or fluorescence detection.
A single oral dose of EGb 761 (100 mg.kg(-1)) had no effect on monoamine levels. However, following chronic (100 mg.kg(-1)/14 days/once daily) treatment, the same dose significantly increased extracellular dopamine and noradrenaline levels, while 5-HT levels were unaffected. Chronic treatment with EGb 761 showed dose-dependent increases in frontocortical dopamine levels and, to a lesser extent, in the striatum. The extracellular levels of HVA and DOPAC were not affected by either acute or repeated doses. Treatment with the main constituents of EGb 761 revealed that the increase in dopamine levels was mostly caused by the flavonol glycosides and ginkgolide fractions, whereas bilobalide treatment was without effect.
CONCLUSIONS AND IMPLICATIONS:
The present results demonstrate that chronic but not acute treatment with EGb 761 increased dopaminergic transmission in the PFC. This finding may be one of the mechanisms underlying the reported effects of G. biloba in improving cognitive function.
11. He´ le`ne Amieva, Ce´ line Meillon, Catherine Helmer1, Pascale Barberger-Gateau1, Jean Franc¸ois Dartigues – Ginkgo Biloba Extract and Long-Term Cognitive Decline:A 20-Year Follow-Up Population-Based Study
Numerous studies have looked at the potential benefits of various nootropic drugs such as Ginkgo biloba extract (EGb761®; Tanakan®) and piracetam (Nootropyl®) on age-related cognitive decline often leading to inconclusive results due to small sample sizes or insufficient follow-up duration. The present study assesses the association between intake of EGb761® and cognitive function of elderly adults over a 20-year period.
METHODS AND FINDINGS:
The data were gathered from the prospective community-based cohort study ‘Paquid’. Within the study sample of 3612 non-demented participants aged 65 and over at baseline, three groups were compared: 589 subjects reporting use of EGb761® at at least one of the ten assessment visits, 149 subjects reporting use of piracetam at one of the assessment visits and 2874 subjects not reporting use of either EGb761® or piracetam. Decline on MMSE, verbal fluency and visual memory over the 20-year follow-up was analysed with a multivariate mixed linear effects model. A significant difference in MMSE decline over the 20-year follow-up was observed in the EGb761® and piracetam treatment groups compared to the ‘neither treatment’ group. These effects were in opposite directions: the EGb761® group declined less rapidly than the ‘neither treatment’ group, whereas the piracetam group declined more rapidly (β = -0.6). Regarding verbal fluency and visual memory, no difference was observed between the EGb761® group and the ‘neither treatment’ group (respectively, β = 0.21 and β = -0.03), whereas the piracetam group declined more rapidly (respectively, β = -1.40 and β = -0.44). When comparing the EGb761® and piracetam groups directly, a different decline was observed for the three tests (respectively β = -1.07, β = -1.61 and β = -0.41).
Cognitive decline in a non-demented elderly population was lower in subjects who reported using EGb761® than in those who did not. This effect may be a specific medication effect of EGb761®, since it was not observed for another nootropic medication, piracetam.
12. Kennedy, Scholey, Wesnes – Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults.
13. Ginkgo biloba
Ginkgo has a long history of use in treating blood disorders and memory issues. It is best known today as way to potentially keep your memory sharp. Laboratory studies have shown that ginkgo improves blood circulation by opening up blood vessels and making blood less sticky. It is also an antioxidant.
For those reasons, ginkgo may improve vein and eye health. Although not all studies agree, ginkgo may help treat dementia (including Alzheimer disease) and intermittent claudication, or poor circulation in the legs. It may also protect memory in older adults.
Ginkgo leaves contain flavonoids and terpenoids, which are both antioxidants. In your body, harmful particles called free radicals build up as you age, and may contribute to heart disease, cancer, and Alzheimer disease. Antioxidants like those found in ginkgo fight off free radicals, and stop them from damaging DNA and other cells.
14. Hemmeter, Annen, Bischof, Brüderlin, Hatzinger, Rose, Holsboer-Trachsler. – Polysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipramine.
15. Woelk H1, Arnoldt KH, Kieser M, Hoerr R. – Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial.
16. Müller, Rolli, Schäfer, Hafner – Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.
17. World Health Organization 2011 – International Statistical Classification of Diseases and Related Health Problems
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.